MacCoss - Acarbose Paper

MacCoss - Acarbose Paper
Acarbose improves late-life physical function in mice of both sexes, but rejuvenates cardiac structure and lipid profile in males only
Data License: CC BY 4.0 | ProteomeXchange: PXD017706
  • Organism: Mus musculus
  • Instrument: Orbitrap Fusion Lumos
  • SpikeIn: No
  • Keywords: data independent acquisition, Type 2 diabetes, acarbose, age-related disease
  • Lab head: Michael MacCoss Submitter: Gennifer Merrihew
Abstract
With an expanding aging population burdened with comorbidities, there is considerable interest in treatments that optimize health in later life. Acarbose (ACA), a drug used clinically to treat Type 2 diabetes (T2DM) can extend mouse lifespan, with greater effect in males than in females. Utilizing a genetically heterogeneous mouse model, we tested the ability of ACA to ameliorate functional, pathological and biochemical changes that occur during aging, and determined which of the effects of age and drug were sex-dependent. In both sexes, ACA prevented age-dependent loss of body mass, in addition to improving grip strength, balance/coordination on an accelerating rotarod, and rotarod endurance. Age-related cardiac hypertrophy was seen only in male mice, and this male-specific aging effect was attenuated by ACA. ACA-sensitive cardiac changes were associated with reduced activation of cardiac growth promoting pathways and decreased abundance of peroxisomal proteins involved in lipid metabolism. ACA further ameliorated age-associated changes in cardiac lipid species, particularly lysophospholipids – changes which have previously been associated with aging, cardiac dysfunction and cardiovascular disease in humans. In the liver, ACA had pronounced effects on lipid handling in both sexes, reducing hepatic lipidosis during aging and shifting the liver lipidome in adulthood, particularly favoring reduced triglyceride accumulation. Our results demonstrate that ACA, already in clinical use for T2DM, has broad-ranging anti-aging effects in multiple tissues, and may have the potential to increase physical function and alter lipid biology to preserve or improve health at older ages.
Experiment Description
Lysis/Digestion - Mouse heart tissue previously probe sonicated in 90 ul of 0.1% RapiGest in 100 mM Tris with phosphatase inhibitors was resuspended in 30 ul of 3X lysis buffer for a final concentration of 5% SDS, 50mM Triethylammonium bicarbonate (TEAB), 2mM MgCl2, 1X HALT phosphatase and protease inhibitors and vortexed. Protein concentration was measured with a BCA assay. Homogenate of 50 ug was added to a process control of 800 ng of yeast enolase protein (Sigma) which was then reduced with 20 mM DTT and alklyated with 40 mM IAA. Lysates were then prepared for S-trap column (Protifi) binding by the addition of 1.2% phosphoric acid and 350 ul of binding buffer (90% Methanol, 100 mM TEAB). The acidified lysate was bound to column incrementally, followed by 3 wash steps with binding buffer to remove SDS and 3 wash steps with 50:50 methanol:chloroform to remove lipids and a final wash step with binding buffer. Trypsin (1:10) in 50mM TEAB was then added to the S-trap column for digestion at 47°C for one hour. Hydrophilic peptides were then eluted with 50 mM TEAB and hydrophobic peptides were eluted with a solution of 50% acetonitrile in 0.2% formic acid. Elutions were pooled, speed vacuumed and resuspended in 0.1% formic acid. A heavy labeled Peptide Retention Time Calibrant (PRTC) mixture (Pierce) was added to each sample. Liquid Chromatography and Mass Spectrometry - One ug of each sample with 150 femtomole of PRTC was loaded onto a 30 cm fused silica picofrit (New Objective) 75 µm column and 3.5 cm 150 µm fused silica Kasil1 (PQ Corporation) frit trap loaded with 3 µm Reprosil-Pur C18 (Dr. Maisch) reverse-phase resin analyzed with a Thermo Easy nano-LC 1200. The PRTC mixture is used to assess quality of the column before and during analysis. Four of these quality control runs are analyzed prior to any sample analysis and then after every six sample runs another quality control run is analyzed. Buffer A was 0.1% formic acid in water and buffer B was 0.1% formic acid in 80% acetonitrile. The 40-minute QC gradient consists of a 0 to 16% B in 5 minutes, 16 to 35% B in 20 minutes, 35 to 75% B in 1 minute, 75 to 100% B in 5 minutes, followed by a wash of 9 minutes and a 30 minute column equilibration. The 110-minute sample LC gradient consists of a 2 to 7% for 1 minutes, 7 to 14% B in 35 minutes, 14 to 40% B in 55 minutes, 40 to 60% B in 5 minutes, 60 to 98% B in 5 minutes, followed by a 9 minute wash and a 30 minute column equilibration. Peptides were eluted from the column with a 50°C heated source (CorSolutions) and electrosprayed into a Thermo Orbitrap Fusion Lumos Mass Spectrometer with the application of a distal 3 kV spray voltage. For the quality control analysis, a cycle of one 120,000 resolution full-scan mass spectrum (350-2000 m/z) followed by a data-independent MS/MS spectra on the loop count of 76 data-independent MS/MS spectra using an inclusion list at 15,000 resolution, AGC target of 4e5, 20 sec maximum injection time, 33% normalized collision energy with a 8 m/z isolation window. For the sample digest, first a chromatogram library of 6 independent injections is analyzed from a pool of all samples within a batch. For each injection a cycle of one 120,000 resolution full-scan mass spectrum with a mass range of 100 m/z (400-500 m/z, 500-600 m/z…900-1000 m/z) followed by a data-independent MS/MS spectra on the loop count of 26 at 30,000 resolution, AGC target of 4e5, 60 sec maximum injection time, 33% normalized collision energy with a 4 m/z overlapping isolation window. The chromatogram library data is used to quantify proteins from individual sample runs. These individual runs consist of a cycle of one 120,000 resolution full-scan mass spectrum with a mass range of 350-2000 m/z, AGC target of 4e5, 100 ms maximum injection time followed by a data-independent MS/MS spectra on the loop count of 76 at 15,000 resolution, AGC target of 4e5, 20 sec maximum injection time, 33% normalized collision energy with an overlapping 8 m/z isolation window. Application of the mass spectrometer and LC solvent gradients are controlled by the ThermoFisher XCalibur data system. Data Analysis - Thermo RAW files were converted to mzML format using Proteowizard (version 3.0.19045) using vendor peak picking and demultiplexing. Chromatogram spectral libraries were created using default settings (10 ppm tolerances, trypsin digestion, HCD b- and y-ions) of Walnut in EncyclopeDIA (version 0.9.0) using the Uniprot mouse canonical FASTA. Quantitative spectral libraries were created by mapping spectral to the chromatogram spectral library using EncyclopeDIA requiring a minimum of 3 quantitative ions and filtering peptides at a 1% FDR using Percolator 3.01. The quantitative spectral library is imported into Skyline with the mouse uniprot FASTA as the background proteome to map peptides to proteins. The mzML data is imported and all data is TIC normalized and calibrated to the batch reference.
Sample Description
Each sample batch was 24 individual mouse heart tissue samples, representing 4 randomly selected mice from 6 groups, and 2 pooled references for a total of 26 samples per batch. The first reference was a pool composed of 32 samples, 4 randomly selected mice from 8 groups (2 of the 8 groups not represented in this study). The second reference was a pool composed of 24 samples, 4 randomly selected mice from 6 groups (none of the 6 groups represented in this study). Both references were homogenized, aliquoted, frozen, and used to compare between batches and as a “universal reference” for comparison between similar proteomic studies. Six groups are: 1) Male-Sham-Young-Control, 2) Male-Sham-Old-Control, 3) Male-Sham-Old-Aca, 4) Female-Sham-Young-Control, 5) Female-Sham-Old-Control, 6) Female-Sham-Old-Aca. Reference 1 - Sham and Reference 2 - Cast
Created on 2/24/20, 3:54 PM
Clustergrammer Heatmap
 
Download
7memberCommunity_PlateB.sky.zip2025-07-02 21:47:565012122470
7memberCommunity_PlateA.sky.zip2025-07-02 21:47:565012122470
7memberCommunity_PlateD.sky.zip2025-07-02 21:47:565012122470
7memberCommunity_PlateC.sky.zip2025-07-02 21:47:565012122470
7memberCommunity_PlateB.sky.zip2025-07-02 21:47:565012122470
210723-ATI-barley-Pt14_2025-02-24_01-08-00.sky.zip2025-07-02 20:45:2110101987330
210423-ATI-barley-Pt13_2025-02-24_01-07-11.sky.zip2025-07-02 20:45:2010101940270
210416-ATI-barley-Pt12_2025-02-24_01-06-33.sky.zip2025-07-02 20:45:1810101938430
210415-ATI-barley-Pt11_2025-02-24_01-05-41.sky.zip2025-07-02 20:45:1610101940290
210302-ATI-barley-Pt10_2025-02-24_01-05-05.sky.zip2025-07-02 20:45:1510101942340
210224-ATI-barley-Pt9_2025-02-24_01-04-22.sky.zip2025-07-02 20:45:1310101940310
210217-ATI-barley-Pt8_2025-02-24_01-03-46.sky.zip2025-07-02 20:45:1210101940290
210210-ATI-barley-Pt7_2025-02-24_01-03-02.sky.zip2025-07-02 20:45:1010101946310
210203-ATI-barley-Pt6_2025-02-24_01-02-20.sky.zip2025-07-02 20:45:0910101950310
210129-ATI-barley-Pt5_2025-02-24_01-01-22.sky.zip2025-07-02 20:45:0710101958310
200731-ATI-barley-Pt4_2025-02-24_01-00-26.sky.zip2025-07-02 20:45:0610101987190
200717-ATI-barley-Pt3_2025-02-24_00-58-01.sky.zip2025-07-02 20:45:0410101987550
200709-ATI-barley-Pt2-Response_2025-02-24_00-56-48.sky.zip2025-07-02 20:45:011010199570
200709-ATI-barley-Pt2_2025-02-24_00-55-11.sky.zip2025-07-02 20:45:0110101991360
200602-ATI-barley-Pt1_2025-02-24_00-25-35.sky.zip2025-07-02 20:44:5910101993310
TPAD_CSF1A_Batch1-multiNF-DIANN.sky.zip2025-07-01 17:49:472,85327,12832,575259,532430
TPAD_CSF1A_Batch1-multiNF-DIANN-grouped.sky.zip2025-07-01 17:41:312,67226,43931,769253,119430
TPAD_CSF1B_Batch2-multiNF-DIANN.sky.zip2025-07-01 15:26:132,85327,12832,575259,532410
TPAD_CSF1B_Batch2-multiNF-DIANN-grouped.sky.zip2025-07-01 15:17:422,67226,43931,769253,119410
TPAD_CSF2A_Batch3-multiNF-DIANN.sky.zip2025-07-01 14:13:302,85327,12832,575259,532430
TPAD_CSF2A_Batch3-multiNF-DIANN-grouped.sky.zip2025-07-01 14:04:582,67226,43931,769253,119430
TPAD_CSF2B_Batch4-multiNF-DIANN.sky.zip2025-07-01 11:21:372,85327,12832,575259,532430
TPAD_CSF2B_Batch4-multiNF-DIANN-grouped.sky.zip2025-07-01 11:09:482,67226,43931,769253,119430
TPAD_CSF3A_Batch5-multiNF-DIANN.sky.zip2025-06-30 15:31:332,85327,12832,575259,532430
TPAD_CSF3A_Batch5-multiNF-DIANN-grouped.sky.zip2025-06-30 15:23:252,67226,43931,769253,119430
TPAD_CSF3B_Batch6-multiNF-DIANN.sky.zip2025-06-30 14:43:542,85327,12832,575259,532410
TPAD_CSF3B_Batch6-multiNF-DIANN-grouped.sky.zip2025-06-30 14:36:142,67226,43931,769253,119410
TPAD_CSF4_Batch7-multiNF-DIANN.sky.zip2025-06-30 13:55:172,85327,12832,575259,532420
TPAD_CSF4_Batch7-multiNF-DIANN-grouped.sky.zip2025-06-30 13:46:482,67226,43931,769253,119420
TPAD_CSF5_Batch8-multiNF-DIANN.sky.zip2025-06-30 13:02:062,85327,12832,575259,532540
TPAD_CSF5_Batch8-multiNF-DIANN-grouped.sky.zip2025-06-30 11:52:172,67226,43931,769253,119540
METRIC_Eclipse_PSB_All_QCs_2025-06-27_01-27-04.sky.zip2025-06-26 22:27:1516662336
Exp_CSF_GPF_A_2024-05-06_21-16-47.sky.zip2025-06-25 18:12:201,8297,3787,37855,04010
2024-05 CSF LIT GPF-MSFragger-3.sky.zip2025-06-25 18:12:201,0825,0956,01940,40160
240207_gpf_2024-06-04_10-24-18.sky.zip2025-06-25 18:12:201,2886,98410,593126,08610
230305_ev2_prm_final_inj1_2024-06-04_07-32-10.sky.zip2025-06-25 18:12:207222,0892,08914,449420
230124_p2_neo_30min_3500targets_opt_trans_pepleveldilution_2024-06-04_06-58-16.sky.zip2025-06-25 18:12:201,0273,5013,50111,420410
CSF_neurod105_assay_individuals_manual_2024-06-03_15-26-36.sky.zip2025-06-25 18:12:201029029026,345370
Exp_CSF_MMCC_quant_all_adjBound_opttrans_nochick_2024-06-03_14-53-02.sky.zip2025-06-25 18:12:201,2058,3748,37424,934270
OT_GPF_PRM_survey_MMCC_boundaries_opttrans_nochick_2024-06-03_14-36-08.sky.zip2025-06-25 18:12:201,2801,9711,9715,801270
LIT_GPF_survey_newAlign_MMCC_boundaries_opttrans_nochick_2024-06-02_15-26-11.sky.zip2025-06-25 18:12:207982,0352,0355,998270
Aducanumab_Selectivity_2025-06-19_12-58-48.sky.zip2025-06-19 09:59:06448512364
hela_isolation_window_concentration_2000ng.sky.zip2025-06-02 18:36:1910,365188,947223,7653,101,148180
hela_isolation_window_experiment_200ng.sky.zip2025-06-02 18:36:1910,365188,947223,7653,101,148180
hela_isolation_window_experiment_500ng.sky.zip2025-06-02 18:36:1910,364188,947223,7653,101,148180
hela_isolation_window_experiment_1000ng.sky.zip2025-06-02 18:36:1910,365188,947223,7653,101,148180
2025-0405-MMCC-EV-Astral-noimpute_2025-05-29_11-52-05.sky.zip2025-06-02 18:36:194,90737,54742,331335,891420
2025-0405-MMCC-EV-Actis-noimpute_2025-05-29_11-46-45.sky.zip2025-06-02 18:36:195,18541,97847,810380,072420
SMTG-low-value-imputed_2025-05-01_14-22-15.sky.zip2025-06-01 21:38:1710,383187,220217,1092,214,248780
SMTG-MissForest-imputed_2025-05-01_11-41-41.sky.zip2025-06-01 20:04:5710,383187,220217,1092,214,248780
SMTG-nettle-imputed_2025-04-30_12-25-18.sky.zip2025-06-01 18:16:1410,639215,139251,4792,483,959780
SMTG-unimputed_2025-04-30_08-55-40.sky.zip2025-06-01 13:32:5610,639215,139251,4792,483,959780
TEI-REX-unimputed_2025-04-29_15-46-15.sky.zip2025-06-01 11:49:381,30749,85259,007585,987960
TEI-REX-nettle-imputed_2025-04-29_13-36-50.sky.zip2025-06-01 11:15:251,30749,85259,007585,987960
MagNet-holdout-nettle-imputed_2025-05-01_08-50-25.sky.zip2025-06-01 09:40:175,29914,11015,07460,288420
hela_isolation_window_concentration_2000ng.sky.zip2025-05-30 15:25:4610,365188,947223,7653,101,148180
ecoli_large_replicates_loaded_refined_2024-05-30_14-02-04.sky.zip2025-05-30 12:00:183669899894,94080
ecoli_large_replicates_loaded_2024-05-30_14-00-59.sky.zip2025-05-30 12:00:184611,3021,3027,52480
ecoli_large_replicates_2024-05-30_14-00-05.sky.zip2025-05-30 12:00:184611,3021,3027,52400
ecoli_subset_replicates_refined_cv_2024-05-30_13-58-18.sky.zip2025-05-30 12:00:187592,2662,26612,80720
ecoli_subset_replicates_refined_2024-05-30_13-57-25.sky.zip2025-05-30 12:00:187592,4372,43713,60220
ecoli_subset_replicates_2024-05-30_13-56-16.sky.zip2025-05-30 12:00:187592,4372,44130,85720
gpf_results_importer_2024-05-30_13-54-14.sky.zip2025-05-30 12:00:181,1925,3967,42785,67310
gpf_results_manual_2024-05-30_13-52-23.sky.zip2025-05-30 12:00:181,1925,3967,42785,67310
pq500_100spd_plasma_final_lightheavy_replicates_2024-05-30_13-50-10.sky.zip2025-05-30 11:58:415798181,62213,699100
pq500_60spd_plasma_final_lightheavy_replicates_2024-05-30_13-48-26.sky.zip2025-05-30 11:58:415798181,62213,876100
pq500_100spd_plasma_final_replicates_2024-05-30_13-47-38.sky.zip2025-05-30 11:58:415798188187,081100
pq500_60spd_plasma_final_replicates_2024-05-30_13-46-43.sky.zip2025-05-30 11:58:415798188186,977100
pq500_100spd_plasma_multireplicate_results_refined_2024-05-30_13-46-07.sky.zip2025-05-30 11:58:415798188187,08110
pq500_60spd_plasma_multireplicate_results_refined_2024-05-30_13-45-40.sky.zip2025-05-30 11:58:415798188186,97710
pq500_100spd_plasma_multireplicate_results_2024-05-30_13-45-07.sky.zip2025-05-30 11:58:415798188187,65120
pq500_60spd_plasma_multireplicate_results_2024-05-30_13-44-21.sky.zip2025-05-30 11:58:415798188187,60120
pq500_100spd_neat_multireplicate_results_refined_2024-05-30_13-43-42.sky.zip2025-05-30 11:58:415798188187,68910
pq500_60spd_neat_multireplicate_results_refined_2024-05-30_13-43-05.sky.zip2025-05-30 11:58:415798188187,60110
pq500_100spd_neat_multireplicate_results_2024-05-30_13-42-26.sky.zip2025-05-30 11:58:4157981881811,08810
pq500_60spd_neat_multireplicate_results_2024-05-30_13-41-26.sky.zip2025-05-30 11:58:4157981881811,08810
pq500_60spd_neat_multireplicate_2024-05-30_13-40-53.sky.zip2025-05-30 11:58:4157981881811,08800
hela_isolation_window_experiment_200ng.sky.zip2025-05-30 01:29:3910,365188,947223,7653,101,148180
hela_isolation_window_experiment_500ng.sky.zip2025-05-30 00:53:5310,364188,947223,7653,101,148180
hela_isolation_window_experiment_1000ng.sky.zip2025-05-29 23:15:1110,365188,947223,7653,101,148180
2025-0405-MMCC-EV-Astral-noimpute_2025-05-29_11-52-05.sky.zip2025-05-29 12:13:324,90737,54742,331335,891420
2025-0405-MMCC-EV-Actis-noimpute_2025-05-29_11-46-45.sky.zip2025-05-29 12:03:295,18541,97847,810380,072420
20240709_OBIPhA.sky.zip2025-05-16 09:25:5133337235120
Swaney-IPMS-Data-DIANN_2025-05-15_11-53-43.sky.zip2025-05-15 12:02:265,18545,78152,836422,661150
Vial Comparison Post 01152025 v1 (not daily)_2025-04-29_15-52-29.sky.zip2025-04-30 21:22:23102424190
Vial Comparison Pre v2_2025-04-29_15-49-25.sky.zip2025-04-30 21:22:23102424230
ATI_Samples_2023_2025-04-26_13-39-03.sky.zip2025-04-28 10:30:14132448280420
ATI_Response_2023_2025-04-26_13-25-06.sky.zip2025-04-28 10:30:14132448280180
ATI_Samples_2022_2025-02-20_23-31-07.sky.zip2025-04-28 10:30:10122346268480
ATI_Samples_2021_2025-02-20_23-21-52.sky.zip2025-04-28 10:30:08122346268300
2023_ATIsamples_circe_2025-02-20_13-24-11.sky.zip2025-04-25 14:58:17132243250960
2022_ATIsamples_circe_2025-02-20_13-17-06.sky.zip2025-04-25 14:58:09122243250970
2021_ATIsamples_circe_2025-02-20_13-06-53.sky.zip2025-04-25 14:58:02122243250940
deamidation_localization_gS_7-18_2025-04-24_20-52-46.sky.zip2025-04-25 12:05:181441810
synthetic_heavy_gS_peptides_4-21-25_2025-04-21_16-42-22.sky.zip2025-04-25 12:05:15161166320